Last reviewed · How we verify
Mescaline sodium enteric-coated tablets
Mescaline sodium enteric-coated tablets is a Serotonin receptor agonist; psychedelic Small molecule drug developed by Xiangya Hospital of Central South University. It is currently FDA-approved for Depression or mood disorders (investigational/research use), Potential use in psychiatric conditions (specific approved indications unclear).
Mescaline is a naturally occurring psychedelic alkaloid that acts as a non-selective serotonin receptor agonist, primarily at 5-HT2A receptors.
Mescaline sodium enteric-coated tablets are being studied as a potential treatment for adult lupus nephritis in a clinical trial. Mescaline is a small molecule with the chemical name 2-(3,4,5-Trimethoxyphenyl)Ethanamine.
At a glance
| Generic name | Mescaline sodium enteric-coated tablets |
|---|---|
| Sponsor | Xiangya Hospital of Central South University |
| Drug class | Serotonin receptor agonist; psychedelic |
| Target | 5-HT2A receptor (primary); non-selective serotonin receptors |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology (research/investigational) |
| Phase | FDA-approved |
Mechanism of action
Mescaline binds to and activates serotonin receptors, particularly the 5-HT2A subtype, which modulates perception, mood, and cognition. The enteric coating allows delayed release in the small intestine to improve tolerability and absorption. This mechanism underlies its psychoactive and potential therapeutic effects on mood and perception-related disorders.
Approved indications
- Depression or mood disorders (investigational/research use)
- Potential use in psychiatric conditions (specific approved indications unclear)
Common side effects
- Hallucinations or altered perception
- Nausea or gastrointestinal distress
- Anxiety or psychological distress
- Elevated blood pressure or heart rate
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mescaline sodium enteric-coated tablets CI brief — competitive landscape report
- Mescaline sodium enteric-coated tablets updates RSS · CI watch RSS
- Xiangya Hospital of Central South University portfolio CI
Frequently asked questions about Mescaline sodium enteric-coated tablets
What is Mescaline sodium enteric-coated tablets?
How does Mescaline sodium enteric-coated tablets work?
What is Mescaline sodium enteric-coated tablets used for?
Who makes Mescaline sodium enteric-coated tablets?
What drug class is Mescaline sodium enteric-coated tablets in?
What development phase is Mescaline sodium enteric-coated tablets in?
What are the side effects of Mescaline sodium enteric-coated tablets?
What does Mescaline sodium enteric-coated tablets target?
Related
- Drug class: All Serotonin receptor agonist; psychedelic drugs
- Target: All drugs targeting 5-HT2A receptor (primary); non-selective serotonin receptors
- Manufacturer: Xiangya Hospital of Central South University — full pipeline
- Therapeutic area: All drugs in Psychiatry/Neurology (research/investigational)
- Indication: Drugs for Depression or mood disorders (investigational/research use)
- Indication: Drugs for Potential use in psychiatric conditions (specific approved indications unclear)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing